预算影响分析中药品市场份额的计算方法探讨

目的 探讨预算影响分析(BIA)中药品市场份额的计算方法,以期为BIA研究提供新思路.方法 针对部分药品具有多种适应证或药品说明书适应证不够明确且与报销目录适应证表述不一致的情况,从"人次数"这一概念出发,引入样本医院、每人次平均治疗时间等参数来进行市场份额计算;同时以肝硬化治疗药物为例演示计算过程.结果 与结论 以肝...

Discussion on calculation methods of drug market share in budget impact analysis

OBJECTIVE To investigate the calculation method of drug market share in budget impact analysis(BIA)in order to provide new ideas for BIA research.METHODS In view of the situation that some drugs had multiple indications or the indications in the drug instructions were not clear enough and inconsistent with the indications in the reimbursement catalogue,starting from the concept of“times per person”,the parameters such as sample hospital and average treatment time per person for each time were introduced to develop a new market share calculation method.At the same time,the calculation process was demonstrated by taking the treatment drugs for liver cirrhosis as an example.RESULTS&CONCLUSIONS Taking treatment drugs of liver cirrhosis as an example,the calculation results of market share showed that the results of the two calculation methods were quite different.The market share calculated on the basis of“the number of people”was mostly higher than that calculated on the basis of“times per person”.Compared with the traditional calculation method based on“the number of people”,the calculation method of market share based on“times per person”could calculate the market share more accurately,which could solve the problem that the traditional method didn’t fully consider that most drugs had multiple indications,the indications of drug instructions were not clear enough and inconsistent with the reimbursement catalogue,resulting in inaccurate calculation of market share;at the same time,this method could also be used to try to solve the problem that the total number of patients could not be obtained from epidemiological data based on the average treatment time per person of each time in the sample hospital.This method can be considered when the indications of the target drug are not clear enough or there are multiple indications,or when the researchers collect clinical,epidemiological and medical insurance data to estimate the number of target population,the prediction results of market capacity do not conform to the theoretical logic or actual situation due to the lack of necessary data,or when the target disease has the characteristics of repeated attacks and short course of disease.